New Delhi: India has made a big decision by changing its strategy in the fight against the Karuna epidemic.
According to Indian media, the Drug Controller General of India (DCGI) has approved the bridging trial of the third phase of the Russian vaccine ‘Spontaneous Light’.
A recent study published in the medical journal The Legend found that Sputnik Light had a 78.6 to 83.7% effect against codeine nineteen, much higher than most two-dose vaccines. ۔
Earlier in July, the CDSCO’s subject matter expert committee ruled out the need for third-stage testing of Russian vaccines across the country and refused to authorize Sputnik-Light for emergency use.
The committee noted that the Sputnik-Light Sputnik-V elements were identical and that its security and immunogenicity data in the Indian population had already been prepared in a test.
Also read: Russia has also approved a single dose of the Sputnik vaccine
A recent study of at least 40,000 elderly people in Argentina found that Sputnik Light reduced hospital admissions among the target population from 82.1% to 87.6%.
The Russian Direct Investment Fund (RDIF) last year partnered with Dr. Reddy’s Laboratories for the third phase trial of the Sputnik-V vaccine in India. In April, Sputnik-V received an emergency use authority in India. Was